Advertisement

Topics

Companies Related to "Tumor microenvironment confers mTOR inhibitor resistance invasive intestinal" [Most Relevant Company Matches] RSS

18:12 EST 20th November 2017 | BioPortfolio

Here are the most relevant search results for "Tumor microenvironment confers mTOR inhibitor resistance invasive intestinal" found in our extensive corporate database of over 50,000 company records.

Showing "Tumor microenvironment confers mTOR inhibitor resistance invasive intestinal" Companies 1–25 of 1,000+

Relevant

Presage Biosciences

Presage Biosciences is an oncology company pioneering the incorporation of human efficacy data much earlier in the drug development and clinical trial processes with its patented CIVO arrayed microinjection platform. The CIVO platform allows for simultaneous assessment of multiple drugs or drug combinations directly in a single solid tumor while still in a ...


Mitra Biotech Inc.

Mitra Biotech, with labs in India and the U.S., is engaged in enabling personalized cancer care and rational drug development through its proprietary pre-clinical platform called CANScriptTM. CANScriptTM is a multi-dimensional platform that can recreate the human tumor microenvironment while maintaining patient tumor heterogeneity, signaling networks and t...

TP Therapeutics, Inc.

TP Therapeutics, Inc. (TP) is a clinical-stage structure-based drug design company founded in October 2013 by Dr. J. Jean Cui, the lead inventor of Pfizer’s oncology drug crizotinib. TP Team is focusing on the design and development of novel chemical identities for established oncogene drivers with high incidence of secondary resistant mutations, ...


Ipsat Therapies Oy

Ipsat Therapies Ltd is a Finnish biotechnology company developing its proprietary IPSAT™ (“Intestinal Protection System in Antibiotic Treatment”) family of products for the prevention of hospital infections and antibiotic resistance

Partikula LLC

Partikula is a preclinical stage biotechnology company focused on developing novel therapies for cancer and other diseases based on platform chemistry technologies, including its first-in-class precision Tumor Microenvironment Modifiers (TMEM™), that are designed to deliver therapeutics to the mitochondria and other intracellular targets. Partikula wa...

Verastem, Inc. Verastem, Inc.

Verastem, Inc. (NASDAQ:VSTM) is discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells. Cancer stem cells are an underlying cause of tumor recurrence and metastasis. Verastem is developing small molecule inhibitors of signaling pathways that are critical to cancer stem cell survival and proliferation: FAK, PI3K/mTOR a...

Intellikine, Inc.

Intellikine is a private, clinical-stage company focused on the discovery and development of innovative small molecule drugs targeting the PI3K/mTOR pathway. Intellikine recently announced the start of a Phase I trial for INK128, a selective TORC1/2 inhibitor for oncology and is advancing INK1197, a PI3K-delta/gamma dual-selective inhibitor for the treatment of inflammatory and respiratory diseas...

Onyx Pharmaceuticals, Inc.

Onyx Pharmaceuticals, Inc. is a biopharmaceutical company committed to improving the lives of people with cancer. The company, in collaboration with Bayer HealthCare Pharmaceuticals, Inc., is developing and marketing Nexavar® (sorafenib) tablets, a small molecule drug that is currently approved for the treatment of liver cancer and advanced kidney cancer. Additionally, Nexavar is being investigat...

AdnaGen AG

AdnaGen's diagnostics detect circulating tumor cells in tumor patients. Because tumor cells survive only hours in the bloodstream, there must be an active source, e.g. a relapse or a metastasis. Therefore, the presence of circulating tumor cells is an unfavorable indicator for the progress of the tumor disease. AdnaGen's proprietary 'combination-of-combinations-principle' allows the reliable and v...

Northern Biologics Inc.

Northern Biologics was launched in June 2014 from Blueline Bioscience, a Canadian biotechnology incubator operated by venture capital firm Versant Ventures, in partnership with the University of Toronto and University Health Network’s Princess Margaret Cancer Centre. Headquartered in the MaRS Discovery District of Toronto, the company is developing a ...

Oncomatrix

Oncomatrix is focused on the development of new biopharmaceuticals targeting the tumor stroma. This innovative approach aims not to attack the tumor cells directly but rather the cells supporting the growth and invasiveness of the tumor.

Ardea Biosciences, Inc.

Ardea Biosciences, Inc., of San Diego, California, is a biotechnology company focused on the development of small-molecule therapeutics for the treatment of gout, cancer and human immunodeficiency virus (HIV). RDEA594, our lead product candidate for the treatment of hyperuricemia and gout, is a selective URAT1 transporter inhibitor in Phase 2 clinical development. Our next-generation URAT1 inhib...

National Brain Tumor Society (NBTS)

National Brain Tumor Society is the largest nonprofit organization dedicated to the brain tumor community in the United States. We are fiercely committed to finding better treatments, and ultimately a cure, for people living with a brain tumor today and those who will be diagnosed tomorrow. This means aggressively driving strategic research and advocati...

Society of Interventional Radiology

Interventional radiologists are physicians who specialize in minimally invasive, targeted treatments. They offer the most in-depth knowledge of the least invasive treatments available coupled with diagnostic and clinical experience across all specialties. They use X-ray, MRI and other imaging to advance a catheter in the body, such as in an artery, to treat at the source of the disease internally....

Surface Oncology, Inc.

Surface is creating the next generation of immunotherapies for cancer. To fully unlock the potential of cancer immunotherapy, Surface is targeting a broader set of immune processes by which cancer cells evade immune recognition and attack. Our programs are built upon emerging, proprietary insights about how to improve the immune system’s recognition a...

Paratek Pharmaceuticals Incorporated

Paratek's mission is to overcome the major worldwide problem of bacterial resistance through the application of new proprietary technology and through the development of new antibiotics. Paratek has established two product development programs to identify and develop new pharmaceuticals for the treatment of infectious diseases:The Tetracycline Resistance Project ("Tet Project") based on expertise ...

Surgica Corporation

Surgica Corporation manufactures and markets embolization medical devices for the rapidly growing minimally invasive surgical and therapeutic specialties. Embolization is a minimally invasive procedure that can reduce tumors and vascular malformations by closing off the blood vessels that feed them.The procedure is performed by an interventional radiologist, who advances a catheter through the vas...

Novexel

Novexel is a speciality pharmaceutical company focused on the discovery and development of novel antibiotics designed to overcome the significant global problem of microbial resistance. The ever increasing resistance to marketed antibiotics has led to a clear need for

Canyon Pharmaceuticals

Canyon PharmaceuticalsTM is a privately-held specialty biopharmaceuticals company focused on delivering innovative therapeutic solutions that target important cellular pathways in thrombosis and tumor growth. Canyon holds exclusive world-wide rights to desirudin, a subcutaneous (SC) recombinant direct thrombin inhibitor (DTI), and to pegmusirudin, a pegyla...

Kosan Biosciences

Kosan Biosciences is an established cancer therapeutics company focused on advancing two new classes of anticancer agents through clinical development: heat shock protein 90 (Hsp90) inhibitors and epothilones. Kosan has built an industry-leading position in Hsp90 inhibitors. Hsp90 inhibitors have a novel mechanism of action targeting multiple pathways involved in cancer cell growth and survival....

X4 Pharmaceuticals

X4 Pharmaceuticals is developing novel therapeutics designed to improve immune cell trafficking and increase the ability for T-cells to track and destroy cancer cells. The company’s oral small molecule drug candidates inhibit the CXCR4 receptor, a pathway which plays a central role in promoting the immunosuppressive and pro-angiogenic microenvironment...

Precision Therapeutics

Precision Therapeutics, Inc. is an exciting, fast-growing, personalized cancer management services company founded in 1995 to help physicians determine the most appropriate cancer treatments for their individual patients. We've developed a patented technique for successfully growing human tumor-derived cells in culture and testing the cultivated cells for drug sensitivity and/or resistance. The co...

Memgen, LLC

Memgen is a clinical-stage biotechnology company developing immunotherapies to improve survival and quality of life of patients with cancer, autoimmune conditions and infectious diseases. Memgen’s patent-protected, re-engineered molecules, which are based on the tumor necrosis factor (TNF) superfamily of molecules, target specific receptors express...

S*BIO Pte Ltd

S*BIO is a privately-held biotech company focused on the research and clinical development of novel targeted small molecule drugs for the treatment of cancer with leading programs around histone deacetylases (HDAC) and kinases. S*BIO's lead candidate, SB939, entered the clinic in 2007. SB1518, S*BIO's potent and orally-active JAK2 inhibitor, entered the clinic in 2008 and has received orphan drug ...

Techniclone International Corporation

TECHNICLONE CORPORATION is engaged in the research and development of unique therapeutics for the treatment of cancer: The company utilizes innovative targeting technologies to develop products capable of destroying cancerous tumors throughout the body. The Company's Tumor Necrosis Therapy (TNT) is designed to deliver high doses of radiation directly to the core of the tumor while causing minimal ...


More From BioPortfolio on "Tumor microenvironment confers mTOR inhibitor resistance invasive intestinal"

Quick Search
Advertisement
 

Corporate Database Quicklinks